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UKRAIN AND ITS EMERGING ROLE AS AN ANTINEOPLASTIC 
AGENT IN SYSTEMIC MALIGNANCIES
S. Kapoor
Mechanicsville, VA
I read with great interest the recent article by Boze­
man et al. [�]. Ukrain may inhibit t�mor progression 
in a n�mber of other systemic malignancies.
Ukrain mod�lates secreted protein acidic and rich 
in cysteine �SPARC� expression in renal cell carcino­
mas [�]. As a res�lt it has a negative impact on the 
invasiveness of these t�mors. An inhibitory effect 
is also seen on matrix metalloproteinase­9 expression 
in the renal carcinoma cells. In fact� there have been 
reports of complete resol�tion of metastatic renal 
t�mors following adj�nctive administration of Ukrain 
[�]. Similarly� Ukrain atten�ates Bcl­� levels and ac­
cent�ates Bax levels thereby a�gmenting and pro­
moting apoptosis in prostate carcinomas [4]. It also 
increases the cleaved PARP levels and a�gments the 
expression of FasL. Ukrain also enhances the T­helper 
lymphocyte/T­s�ppressor lymphocyte ratio inside the 
carcinoma th�s f�rther a�gmenting its anti­prolifera­
tive activity [�]. Ukrain also enhances apoptosis in the 
prostate carcinoma cells as is evident by �p­reg�lation 
of p�� [6]. As a res�lt there is increased acc�m�lation 
of carcinomato�s cells in the G�/M phase.
Ukrain administration is accompanied by atten�a­
tion of le�cine as well as gl�tamine levels in bladder 
carcinomas [�]. Ukrain has a negative impact on trans­
port of active free amino acids into the t�mor. As a re­
s�lt intra­t�moral gl�coneogenesis is atten�ated th�s 
decreasing t�mor growth. Ukrain also facilitates s�r­
gical interventions s�ch as mastectomy as the mar­
gins become more clearly defined. Similarly� Ukrain 
a�gments apoptosis in glioblastomas. It mediates 
this effect by �p­reg�lation of “glial fibrillary acidic” 
protein f�nction [8]. Ukrain also has a negative impact 
on SPARC expression in the glioblastoma cells [9].
The above examples clearly ill�strate the significant 
anti­neoplastic effects of Ukrain on systemic t�mors 
and the need for f�rther st�dies in this regard.
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